Health
Humana shares rise after insurer says medical costs came in lower than expected
A Humana office in Louisville, Kentucky, July 31, 2023. Jon Cherry | Bloomberg | Getty Images Humana shares rose Wednesday after the health insurer said medical costs came in lower than expected during its second-quarter earnings report. The results ease investor concerns two months after Humana and rival UnitedHealth Group warned that a surge in […]
Read More
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and belief, Pfizer knowingly […]
Read More
Walgreens is now offering RSV vaccines for older adults
Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images Walgreens is now offering the respiratory syncytial virus vaccine for older adults nationwide, the pharmacy chain said on Tuesday. People ages 60 and older can schedule an appointment this week through Walgreens’ app, website, by phone or by visiting their local pharmacy. […]
Read More
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company’s acquisition of Prometheus Biosciences earlier this year. related investing news Merck swung to a net loss of $5.98 […]
Read More
Pfizer beats on earnings, but revenue misses as Covid product sales plummet
Pavlo Gonchar | Lightrocket | Getty Images Pfizer on Tuesday reported second-quarter adjusted earnings that topped Wall Street’s expectations, but posted revenue that fell short of estimates as Covid product sales plunged. Pfizer reported second-quarter sales of $12.73 billion, down 54% over the same period a year ago. Excluding sales of the company’s Covid vaccine […]
Read More
This little-known pharma stock can rally 50%, Citi says
It’s time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. Citi’s new forecast now implies more than 50% upside from Friday’s close. The company is best known for its RNA-based therapeutics. Analyst David […]
Read More
We’re exiting a health-care name — putting us on the hunt to buy a new stock for the portfolio
We’re taking a hard look at the Bullpen and the rest of the market for new opportunities. Source
Read More
Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time
In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. Justin Sullivan | Getty Images A federal bankruptcy judge on Friday rejected Johnson & Johnson‘s second attempt to resolve tens of thousands of lawsuits alleging the company’s talc baby powder and other talc-based […]
Read More
These health-care companies see opportunity ahead from Alzheimer’s drug approval
As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs, blood tests and other diagnostics, fueling increased demand for these important tools. In earnings calls this week, both GE Healthcare and Quest Diagnostics made references to the potential opportunity here, although neither company put any specific estimates behind their comments. […]
Read More
This under-the-radar biotech could be the next way to play the obesity drug boom
The lucrative market for obesity drugs is dominated by two players right now, but Structure Therapeutics has the potential to enter the category with an oral GLP-1 medication, according to Piper Sandler. Analyst Yasmeen Rahimi initiated coverage of the clinical stage drugmaker with an overweight rating on Thursday, and set a $58 price target, which […]
Read More